Exelixis, Inc. (NASDAQ:EXEL) EVP Sells $36,486.80 in Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 1,162 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the transaction, the executive vice president now owns 498,945 shares of the company’s stock, valued at $15,666,873. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Dana Aftab also recently made the following trade(s):

• On Monday, August 12th, Dana Aftab sold 20,883 shares of Exelixis stock. The shares were sold at an average price of $27.06, for a total transaction of $565,093.98.
• On Wednesday, August 7th, Dana Aftab sold 95,000 shares of Exelixis stock. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00.

Exelixis Price Performance

Shares of EXEL opened at $34.12 on Friday. The firm has a market capitalization of $9.74 billion, a PE ratio of 21.87, a PEG ratio of 0.69 and a beta of 0.54. The company’s 50-day moving average is $27.13 and its 200-day moving average is $24.29. Exelixis, Inc. has a fifty-two week low of $19.20 and a fifty-two week high of $34.45.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. The company had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company’s revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 earnings per share. Analysts predict that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on EXEL shares. TD Cowen upped their price target on shares of Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a report on Monday, October 21st. Piper Sandler upped their price target on shares of Exelixis from $33.00 to $36.00 and gave the company an “overweight” rating in a report on Wednesday. Stephens upped their price target on shares of Exelixis from $23.00 to $29.00 and gave the company an “equal weight” rating in a report on Wednesday. JMP Securities reissued a “market outperform” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Friday, October 11th. Finally, Oppenheimer reissued an “outperform” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Tuesday, July 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.44.

Hedge Funds Weigh In On Exelixis

Several large investors have recently modified their holdings of EXEL. First Trust Direct Indexing L.P. acquired a new position in shares of Exelixis in the first quarter valued at about $250,000. Smith Group Asset Management LLC acquired a new stake in Exelixis during the first quarter worth about $228,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Exelixis by 3.8% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 35,771 shares of the biotechnology company’s stock worth $778,000 after buying an additional 1,301 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Exelixis by 6.1% during the first quarter. Janney Montgomery Scott LLC now owns 60,746 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 3,510 shares in the last quarter. Finally, Nordea Investment Management AB grew its stake in Exelixis by 17.3% during the first quarter. Nordea Investment Management AB now owns 202,292 shares of the biotechnology company’s stock worth $4,835,000 after buying an additional 29,784 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.